secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-06-30T12:00:16+00:00
Accession:  0001437749-26-022086
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar receives FDA Rare Pediatric Disease designation for ALXN1840 in Wilson disease
--------------------------------------------------------------------------------

- FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline) for Wilson disease.
- RPD designation is for therapies treating serious/life-threatening diseases primarily affecting children under 18.
- Upon NDA approval, Monopar may receive a pediatric Priority Review Voucher (PRV).
- PRV can be used for priority review of a subsequent application or sold/transferred to another sponsor.
- CEO Chandler Robinson noted the designation underscores the serious impact of Wilson disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926022086/0001437749-26-022086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926022086/mnpr20260629_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-022086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer